Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction
Cancers · 22.04.2026 · 18 (9) · 1332
DOI: 10.3390/cancers18091332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 22.04.2026. Verfasst von Shunsuke Tatsuki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare real-world PFS between BEV and OLA as maintenance therapy for PSROC, with an exploratory evaluation of clinical outcomes after OLA dose reduction.
Methods
This retrospective multicenter study included 101 patients with first platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer who achieved a response to platinum-based chemotherapy and then received maintenance therapy. Patients were classified into three groups: BEV (n = 34), standard-dose OLA (n = 31), and dose-reduced OLA (n = 36). The primary endpoint was PFS; secondary endpoints were OS and adverse events. Survival outcomes were evaluated using Kaplan–Meier methods and Cox proportional hazards models.
Results
In the primary comparison of all OLA-treated patients versus BEV, OLA was associated with longer PFS (HR 0.48, 95% CI 0.29–0.77), with median PFS of 19 months versus 16 months, respectively. OS did not differ significantly between groups (HR 0.60, 95% CI 0.34–1.05). In exploratory subgroup analyses, patients who underwent OLA dose reduction had numerically longer PFS than those who remained on the full dose; however, this comparison is vulnerable to time-dependent and selection biases and should be interpreted cautiously. Grade ≥ 3 hematologic toxicities were more frequent in the OLA groups but were clinically manageable.
Conclusions
In real-world practice, OLA was associated with longer PFS than BEV in PSROC. Clinically necessary dose reduction appeared feasible without an obvious loss of benefit, although this finding requires cautious interpretation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
- Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, Aomori 039-1104, Japan.
- Department of Obstetrics and Gynecology, Iwate Prefectural Central Hospital, Morioka 020-0066, Japan.
ORCID-Profile: Tadahiro Shoji, Yohei Chiba, Sho Sato, Tsukasa Baba
Zitieren
APA
Tatsuki, S., Shoji, T., Jo, A., Jonai, N., Chiba, Y., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., Aida, T., Miura, F., & Baba, T. (2026). Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction. Cancers, 18(9), 1332. https://doi.org/10.3390/cancers18091332
Vancouver
Tatsuki S, Shoji T, Jo A, Jonai N, Chiba Y, Sato S, et al. Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction. Cancers. 2026;18(9):1332. doi:10.3390/cancers18091332
BibTeX
@article{Tatsuki2026,
author = {Tatsuki, Shunsuke and Shoji, Tadahiro and Jo, Ami and Jonai, Nanako and Chiba, Yohei and Sato, Sho and Takatori, Eriko and Kaido, Yoshitaka and Nagasawa, Takayuki and Kagabu, Masahiro and Aida, Takeshi and Miura, Fumiharu and Baba, Tsukasa},
title = {Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1332},
doi = {10.3390/cancers18091332}
}
EUVIMED